scholarly journals KA-1002, a Novel Lysophosphatidic Acid Signaling Antagonist, Alleviates Bovine Tracheal Cell Disruption and Inflammation

Animals ◽  
2020 ◽  
Vol 10 (2) ◽  
pp. 295 ◽  
Author(s):  
Hee-su Shin ◽  
Miok Kim ◽  
Kwang Soo Kim ◽  
Yong Ki Min ◽  
Chang Hoon Lee
Keyword(s):  
Lysophosphatidic Acid ◽  
Respiratory Diseases ◽  
Therapeutic Agent ◽  
Cell Disruption ◽  
Inflammatory Agent ◽  
Bovine Respiratory Diseases ◽  
Tracheal Cell ◽  
Microbial Infections ◽  
Respiratory Inflammation ◽  
Respiratory Tissue

The industrial livestock environment can cause stress and weakened immunity in cattle, leading to microbial infections which reduce productivity. As such, there is a need for an effective therapeutic agent that can alleviate uncontrolled destructive respiratory inflammation. We found that lysophosphatidic acid (LPA), a potent endogenous stress-induced inflammatory agent, causes respiratory tissue damage and triggers inflammation in bovine bronchial cells. LPA also inflames pulmonary bovine blood vessel cells to produce inflammatory cytokines. These findings strongly suggest that LPA is a highly important endogenous material exacerbating bovine respiratory diseases. We further identified a novel LPA-signaling antagonist, KA-1002, and showed that it alleviated LPA-mediated bovine tracheal cell disruption and inflammation. Therefore, KA-1002 could potentially serve as a novel therapeutic agent to maintain physiologically healthy and balanced conditions in bovine respiratory tracts.

scholarly journals Should hydrogen therapy be included in a musculoskeletal medicine routine?

F1000Research ◽  
2016 ◽  
Vol 5 ◽  
pp. 2659 ◽  
Author(s):  
Sergej M. Ostojic
Keyword(s):  
Health Professionals ◽  
Molecular Hydrogen ◽  
Therapeutic Agent ◽  
Metabolic Diseases ◽  
Neuromuscular Disorders ◽  
Surrogate Markers ◽  
Musculoskeletal Medicine ◽  
Inflammatory Agent ◽  
Medicinal Properties ◽  
Novel Therapeutic

Molecular hydrogen (H2) has recently been recognized as a potential novel therapeutic agent in biomedicine. Initially proposed to be a possible treatment for certain types of neuromuscular disorders, cardio-metabolic diseases and cancer, H2 improved clinical end-points and surrogate markers in several clinical trials, mainly acting as an anti-inflammatory agent and powerful antioxidant. In this paper, the medicinal properties of H2 in musculoskeletal medicine are discussed with the aim to provide an updated and practical overview for health professionals working in this field.

scholarly journals Advances in pulmonary drug delivery targeting microbial biofilms in respiratory diseases

Nanomedicine ◽  
2021 ◽  
Author(s):  
Ankur Sharma ◽  
Dhruv Kumar ◽  
Kajal Dahiya ◽  
Susan Hawthorne ◽  
Saurabh Kumar Jha ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Respiratory Diseases ◽  
Pulmonary Infection ◽  
Respiratory Infections ◽  
Treatment Modalities ◽  
Pulmonary Infections ◽  
Microbial Biofilms ◽  
Effective Treatment Modality ◽  
Microbial Infections ◽  
Suitable Treatment

The increasing burden of respiratory diseases caused by microbial infections poses an immense threat to global health. This review focuses on the various types of biofilms that affect the respiratory system and cause pulmonary infections, specifically bacterial biofilms. The article also sheds light on the current strategies employed for the treatment of such pulmonary infection-causing biofilms. The potential of nanocarriers as an effective treatment modality for pulmonary infections is discussed, along with the challenges faced during treatment and the measures that may be implemented to overcome these. Understanding the primary approaches of treatment against biofilm infection and applications of drug-delivery systems that employ nanoparticle-based approaches in the disruption of biofilms are of utmost interest which may guide scientists to explore the vistas of biofilm research while determining suitable treatment modalities for pulmonary respiratory infections.

Novel Coronavirus (COVID-19) Outbreak: Hope and Search for Effective Therapeutic Agent

2020 ◽  
Vol 17 (8) ◽  
pp. 940-942
Author(s):  
Saurabh Kumar
Keyword(s):  
Drug Therapy ◽  
Respiratory Diseases ◽  
Therapeutic Agent ◽  
Effective Therapy ◽  
High Rate ◽  
Major Threat ◽  
Common Drug ◽  
Global Pandemic ◽  
The World ◽  
Novel Coronavirus

Background: Novel Coronavirus (COVID-19), respiratory diseases and a major threat to mankind is spreading at an unstoppable rate affecting almost every part of the world with Europe being the most affected continent. Originated from China in December 2019 with sequence homology similar to SARS having a high rate of mutation has created a global pandemic with no effective therapy available. Objective: This editorial summarizes the list of potential antiviral drugs or other effective therapy that is in the clinical trial. Methods: The literature search is based on recent publications (year, 2020) available on PubMed and drug/therapy registered on the ClinicalTrial.gov portal. Results: Hydroxychloroquine, tocilizumab, lopinavir/ritonavir, remdesivir, and convalescent plasma are some of the most common drug/therapy that has come as a hope against COVID-19. Conclusion: In view of the current COVID-19 situation, more rigorous efforts are needed. Drugs with better outcomes need more exploration.

scholarly journals Duration of immunity of a four-valent vaccine against bovine respiratory diseases

2017 ◽  
Vol 86 (4) ◽  
pp. 325-332 ◽  
Author(s):  
Corinne Philippe-Reversat ◽  
David Homer ◽  
Claude Hamers ◽  
Sylvie Brunet ◽  
Milan Huňady
Keyword(s):  
Respiratory Diseases ◽  
Clinical Signs ◽  
Mannheimia Haemolytica ◽  
Protective Effects ◽  
Consistent Finding ◽  
Post Vaccination ◽  
Bovine Respiratory Diseases ◽  
Transmission Chain ◽  
Syncytial Virus ◽  
The Individual

This study demonstrated the duration of immunity over 6 months of a vaccine against key bovine respiratory disease pathogens: Parainfluenza 3, Bovine Respiratory Syncytial Virus, Bovine Viral Diarrhoea and Mannheimia haemolytica. This was performed by challenge on colostrum-deprived calves at the age of 2 weeks. Recent European field isolates were used as challenge strains. Clinical signs and pathogen excretion or presence were monitored. Field relevance of the viral challenge strains was analysed using phylogenic analysis. Significant reduction of excretion of the 3 viruses in vaccinated animals was a consistent finding, demonstrating the efficacy of the vaccine. Reducing shedding is indeed key to interrupting the infection transmission chain and helping to achieve the protective effects of immunisation that extend beyond the individual. A significant reduction of clinical signs and lung lesions following the Mannheimia haemolytica challenge was also observed in vaccinated animals versus controls. Comparison of the challenge strains to an array of global and European strains, including recent ones, demonstrated a high genetic proximity, supporting the potential for the vaccine to maintain similar levels of efficacy in the field over a 6-month period post vaccination.

scholarly journals THE EMERGING ROLE OF SERRATIOPEPTIDASE IN ORAL SURGERY: LITERATURE UPDATE

2018 ◽  
Vol 11 (3) ◽  
pp. 19 ◽  
Author(s):  
Santhosh Kumar Mp
Keyword(s):  
Proteolytic Enzyme ◽  
Therapeutic Agent ◽  
Oral Surgery ◽  
Maxillofacial Surgery ◽  
Oral And Maxillofacial Surgery ◽  
Medical Field ◽  
Enzyme Preparations ◽  
Inflammatory Agent ◽  
Anti Inflammatory

 Serratiopeptidase, a proteolytic enzyme derived from Serratia E-15 species enterobacteria, is widely used in medical field for its anti-inflammatory, anti-edemic properties, and analgesic properties. It is being used commonly in various specialties such as orthopedics, otolaryngology, gynecology, surgery, pulmonology, ophthalmology, and dentistry. Research has shown that serratiopeptidase is the most effective anti-inflammatory agent compared to other enzyme preparations. This article reviews the efficacy, safety, and applications of serratiopeptidase in oral surgery. This article also discusses the mechanism of action of serratiopeptidase, its contraindications and complications. From the recently published literature, it is clear that the role of serratiopeptidase as a therapeutic agent in oral and maxillofacial surgery is expanding and they hold a promising future as a broad-spectrum anti-inflammatory drug with minimal side effects and complications. Further, research will broaden their applications in the field of medicine and dentistry.

Artificial Intelligence (AI) Infused Cow Necklace - For Diagnosis Of Bovine Respiratory Diseases

2018 ◽  
Author(s):  
Chandrasekar Vuppalapati ◽  
Rajasekar Vuppalapati ◽  
Sharat Kedari ◽  
Anitha Ilapakurti ◽  
Archana Ramalingam ◽  
...  
Keyword(s):  
Artificial Intelligence ◽  
Respiratory Diseases ◽  
Bovine Respiratory Diseases
Sign in / Sign up

Export Citation Format

Share Document